Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin, Non-Pharmacologic Treatment of HF – American College of Cardiology
In this week’s View, Dr. Eagle looks at a sex-based analysis of short-term dual antiplatelet therapy (DAPT) in patients receiving percutaneous coronary intervention (PCI) who are deemed at high-risk for bleeding. He then discusses the potential value of dapagliflozin in patients with severe heart failure (HF). Finally, Dr. Eagle explores non-pharmacologic therapies to reduce morbidity and improve function in HF patients. Keywords: Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention,
